iRadimed to price IPO of 1.75 million shares between $5.00 and $6.00

Roth Capital is bookrunning manager; co-manager Monarch assists

By Devika Patel

Knoxville, Tenn., July 9 – iRadimed Corp. will sell 1.75 million common shares in its initial public offering with a 45-day greenshoe option of 262,500 additional shares, according to a Form S-1/A filed Wednesday with the Securities and Exchange Commission. The deal was announced on June 18.

The shares will be sold at a price expected to fall between $5.00 and $6.00 per share.

Roth Capital Partners is the bookrunning manager. Monarch Capital Group is the co-manager.

Proceeds will be used for sales and marketing efforts, research and development, working capital and other general corporate purposes.

The provider of non-magnetic intravenous infusion pump systems is based in Winter Park, Fla. The company intends to list its common stock on the Nasdaq under the symbol “IRMD.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.